Gene-Editing Stocks Plunge on Editas CEO Exit, Crispr Downgrade
This article is for subscribers only.
Gene-editing companies are among the worst-performing biotechnology stocks Tuesday after Editas Medicine’s chief executive officer left and Citi questioned Crispr Therapeutics’ data.
Editas Medicine Inc. plunged as much as 22 percent after Katrine Bosley stepped down as CEO and also resigned from the board. The change was a “personal decision” by Bosley and is “occurring at a natural transition point for the company and also from a position of strength,” Cristi Barnett, an Editas spokeswoman, said in an emailed statement.